Skip to main content

Starling Oncology, Inc.

corporate_fare Company Profile

Starling Oncology, Inc.

STLN·NASDAQ·Industrial Applications And Services·CIK 0001799191

Starling Oncology, Inc. (STLN) was formed in 2007, initially as a collection of community oncology practices in southern California. The company has evolved to be a national leader in oncology care, focusing on reducing costs while utilizing clinical best practices and technology. Starling Oncology provides oncology, hematology, specialty infusion, and oral pharmacy services on a fee-for-service basis, and also enrolls patients in clinical trials. A core part of its mission involves partnering with managed care providers and other risk-bearing entities to manage the risk and patient coordination for cancer treatment episodes. This is achieved through gain/loss sharing, capitation, and full delegation contracts at the population level, allowing Starling Oncology to control outpatient treatment for both medical oncology (IV-based infusion therapy) and radiation oncology (radiation therapy using linear accelerator equipment). Starling Oncology treats patients across 17 markets and five states in the United States. Its network includes 65 clinics owned by affiliated physicians and staffed with 116 providers, 81 independently-owned clinics contracted with Starling Oncology's managed services organization, and a contracted network of 198 independent providers unaffiliated with Starling Oncology, particularly where Starling Oncology acts as the fully delegated market manager under a value-based contract. As of December 31, 2025, Starling Oncology managed approximately 2.0 million patients under value-based agreements through this network. The company's Patient Services Fee for Service business line provides medical care for physician services, in-house infusion, radiation, and outpatient blood product transfusions, along with 24/7 patient support.

Starling Oncology, Inc. (NASDAQ:STLN) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 3 items for STLN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 8/10. Across its 3 most recent items scored 7 or higher, the top rating is 8/10, with 2 rated 8 or above. Recent SEC coverage for STLN spans 4, 10-Q.

Recent high-impact activity:

  • 10% Owner Chernett Sells $11.4M of Starling Stock, Buys Small Share/Option Lots, Owes 16(b) Disgorgement
  • Starling Oncology Q3 10-Q: Revenue Up 24.3%, $11.6M Debt-Extinguishment Loss, Going-Concern Language
  • Starling Oncology Posts Second Straight Positive Adjusted EBITDA, Raises Low End of FY26 Outlook

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$502.73M
Net Income
-$60.61M
Diluted EPS
-$0.54
Op. Cash Flow
-$24.59M
Free Cash Flow
-$27.79M
Operating Income
-$36.08M
Cash & Equivalents
$33.56M
Total Debt
$77.4M
Debt / Equity
-4.92×
Net Margin
-12.1%
Shares Outstanding
98.86M sh
Source: 10-K · filed 2026-03-12 · accession 0001799191-26-000007

Short Interest & Short Volume

5.42 days to cover

FINRA reported short interest of 6,840,807 shares in STLN as of the October 30, 2026 settlement, a 4.7% increase from the prior period — about 5.4 days to cover at its recent average daily volume. On November 20, 2026, 11.8% of STLN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)6,840,807 shares as of October 30, 2026
Change vs prior period▲ 4.7%
Days to cover5.42 at avg daily volume of 1,263,262
Daily short volume (FINRA facilities)11.8% of 2,628,823 shares on November 20, 2026
5-day average short volume22.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with S →
$2.99 -0.33% today
52-week range · as of 2026-11-10 $2.32 – $7.13
Market cap
$305.97M
Volume
5.9M (1.5× avg)
3-mo avg 4M
Live data · 2026-11-22 12:37 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed STLN - Latest Insights

STLN
Nov 10, 2026, 6:33 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $4.36
Real-time Price: $2.99 info
Change: -$1.37 (-31%) info
Market Cap: $305.973M info
STLN
Nov 05, 2026, 6:03 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.84
Real-time Price: $2.99 info
Change: -$2.85 (-49%) info
Market Cap: $305.973M info
STLN
Nov 05, 2026, 4:06 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $6.41
Real-time Price: $2.99 info
Change: -$3.42 (-53%) info
Market Cap: $305.973M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets